Involvement of SIRT1 in Zn\textsuperscript{2+}, Streptozotocin, Non-Obese Diabetic, and Cytokine-Mediated Toxicities of β-cells

Christian T. Sheline
Louisiana State University Health Sciences Center, LA, USA

Abstract

Zn\textsuperscript{2+} toxicity is implicated in pancreatic β-cell death that occurs secondarily to: streptozotocin exposure in vitro; and both autoimmune attack or streptozotocin in vivo models of T1DM. This is demonstrated by reduced β-cell death or diabetic incidence in vitro or in NOD mice after treatment with Zn\textsuperscript{2+} preferring chelators, pyruvate, nicotinamide, a reduced zinc diet, sirtuin inhibitors, or zinc transporter knockout. These therapeutics are also demonstrated to be efficacious against Zn\textsuperscript{2+} neurotoxicity.

Aims: To determine if the sirtuin pathway is involved in Zn\textsuperscript{2+}-, streptozotocin-, or cytokine-mediated β-cell death in vitro, and streptozotocin-, or NOD induced T1DM in vivo.

Methods: Sensitivity of MIN6 cells expressing empty vector, sirtuin protein-1 (SIRT1) or its siRNA, to Zn\textsuperscript{2+}, streptozotocin, or cytokines, and effects on NAD\textsuperscript{+} levels were determined. Covariance of manipulating SIRT1 levels with diabetic incidence was tested in vivo.

Results: 1) sirtuin pathway inhibition or SIRT1 knockdown attenuated Zn\textsuperscript{2+}-, STZ-, and cytokine-mediated toxicity and NAD\textsuperscript{+} loss in β-cells, 2) SIRT1 overexpression potentiated these toxicities, 3) young SIRT1 β-cell transgenic mice have improved glucose tolerance under basal conditions, but upon aging showed increased sensitivity to streptozotocin compared to SIRT1 +/- mice, and 4) SIRT1 +/- mice in an NOD background or exposed to streptozotocin trended toward reduced diabetic incidence and mortality compared to wildtype.

Conclusions: These results have implicated SIRT1-mediated NAD\textsuperscript{+} loss in Zn\textsuperscript{2+}, STZ, or cytokine toxicities of MIN6, and in NOD or streptozotocin T1DM animal models. Modulation of β-cell Zn\textsuperscript{2+} and NAD\textsuperscript{+} levels, and the sirtuin pathway could be novel therapeutic targets for T1DM.

Keywords: Sirtuins; NAD\textsuperscript{+}; MIN6; SIRT1 knockout

Abbreviations: BESTO: β-cell SIRT1 Overexpressing mice; CaEDTA: Ethylene Diamine Tetra-Acetic acid-Calcium salt; GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase; HD: High-Density cultures; IFN-γ: Interferon Gamma; IL-1β: Interleukin-1 Beta; MEM: Minimal Essential Medium; MLDS: Multiple Low-Dose Streptozotocin; mM: Millimol/L; MTT: 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium Bromide; Nampt: Nicotinamide Phosphoribosyl Transferase; Naph: 2-hydroxynaphthaldehyde; N: Nicotinamide; NAD\textsuperscript{+}: Nicotinamide adenine dinucleotide; NOD: Non-Obese Diabetic; PDH: Pyruvate Dehydrogenase; ROS: Reactive Oxygen Species; Sirtuin; siRNA: Small inhibitory RNA; SIRT1: Sirtuin protein 1; STZ: Streptozotocin; TNF-α: Tumor Necrosis Factor-alpha; T1DM: Type-1 Diabetes; T2DM: Type-2 Diabetes; uM: Micromol/L; Zn\textsuperscript{2+}: Zinc; [Zn\textsuperscript{2+}]: Intracellular Zinc concentration; ZnT5: Zinc Transporter 5

Introduction

Type-1 diabetes (T1DM) is an autoimmune disease resulting from specific T-lymphocyte-, ROS-, and cytokine-mediated destruction of the insulin-producing β-cells of the islets of Langerhans resulting in dysregulation of blood glucose [1]. The development of T1DM is reduced by treatment with T-cell and cytokine inhibitors, and ROS scavengers [2]. These oxidative processes are suggested to alter the NAD+/NADH ratio and inhibit proteins involved in energy metabolism and glycolysis causing the accumulation of triosephosphates [3,4]. Inhibitors of NAD\textsuperscript{+} catabolism have been demonstrated to attenuate diabetic incidence in models of T1DM [5,6]. NAD\textsuperscript{+} loss is linked to diabetes. Heterozygous knockout of the rate limiting enzyme in NAD\textsuperscript{+} synthesis (Nampt), causes reduced insulin secretion [7]. Also, Nampt and NAD\textsuperscript{+} levels are reduced in T2DM and the aging or high-fat diet models thereof. Restoration of NAD\textsuperscript{+} by nicotinamide mononucleotide precursor supplementation, attenuates diabetes in aging and high-fat diet mouse models of T2DM [8].

We recently showed that just prior to becoming diabetic, NOD mice demonstrate increased punctate Zn\textsuperscript{2+} staining in islets which is attenuated by a reduced Zn\textsuperscript{2+} diet, or zinc transporter 5 (ZnT5) knockout. Triweekly pyruvate or nicotinamide injections, chronic treatment with a reduced zinc diet, or knockout of the zinc transporter 5 (ZnT5) gene delay onset of diabetic incidence and animal mortality by reducing pancreatic zinc and/or maintaining β-cell NAD\textsuperscript{+} levels and mass [9]. This complements the beneficial effects demonstrated for Zn\textsuperscript{2+} chelation against acute or multiple low dose streptozotocin exposures [10,11]. Zinc neurotoxicity in vitro or in vivo induces NAD\textsuperscript{+} loss and glycylglycine inhibition resulting in increased triosephosphates and death in a manner exactly equivalent to that seen in β-cells. These results are

*Corresponding author: Christian T. Sheline, Department of Ophthalmology and The Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, 2020 Gravier St., Suite D, New Orleans, LA 70112, USA, Tel: (504) 599-0860; Fax: (504) 599-0891; E-mail: cshelie@lsuhsc.edu

Received March 20, 2011; Accepted May 28, 2012; Published May 31, 2012

Citation: Sheline CT (2012) Involvement of SIRT1 in Zn\textsuperscript{2+}, Streptozotocin, Non-Obese Diabetic, and Cytokine-Mediated Toxicities of β-cells. J Diabetes Metab 3:193. doi:10.4172/2155-6156.1000193

Copyright: © 2012 Sheline CT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Zn\textsuperscript{2+} and \(\beta\)-cell death

Zn\textsuperscript{2+} is present in the pancreas at the highest concentration anywhere in the body, and within the pancreas is concentrated in the secretory granules of \(\beta\)-cells [10]. In the \(\beta\)-cell, Zn\textsuperscript{2+} allows insulin processing and crystallization in the secretory granules [15,16]. Significant amounts of free Zn\textsuperscript{2+} are also released from \(\beta\)-cell secretory granules [17,18]. As \(\beta\)-cells contain most of the pancreatic Zn\textsuperscript{2+}, its toxic release, by the immune response or exposure to ROS/streptozotocin, would help explain the specificity of \(\beta\)-cell death in type-1 diabetes [19,20]. Zn\textsuperscript{2+} released intra- or extra-cellularly by diabetic conditions is postulated to induce detrimental intracellular effects on NAD\textsuperscript{+} levels through activation of the sirtuin pathway. The NAD\textsuperscript{+} loss results in glycolytic inhibition which is prevented by restoration of NAD\textsuperscript{+} levels using nicotinamide, sirtuin inhibition, and pyruvate, but not lactate (Figure 1). In these studies, we examined the deleterious effects that Zn\textsuperscript{2+}-mediated NAD\textsuperscript{+} loss had in facilitating \(\beta\)-cell death. We propose that immune-, and ROS-mediated dysfunctions of energy metabolic pathways could be potentiated by Zn\textsuperscript{2+} release, and sirtuin-mediated loss of NAD\textsuperscript{+}. We studied the effects of SIRT1 overexpression or knockdown in MIN6 cultures on NAD\textsuperscript{+} loss and Zn\textsuperscript{2+}, STZ, or cytokine toxicities, and the effect of SIRT1 expression on the streptozotocin or NOD in vivo models of T1DM.

Experimental Procedures

Cell culture and toxicity studies

The MIN6 cell line, MIN6, was used to generate stably transformed cell lines overexpressing SIRT1 (760% of control, MIN6-Sir2OE1), an siRNA to SIRT1 (resulting in 28% of control expression, MIN6-Sir2KD1), and their empty vector control lines [21]. These lines were maintained in modified Dulbecco's medium (DMEM) + 15% supplemented bovine serum, 1% L-glutamine, 0.1% penicillin/streptomycin, 200 microg/mL of G418, and 29 microg/mL \(\beta\)-mercaptoethanol. Cell lines were passaged at 50-70% confluent using 0.05% trypsin/0.02% EDTA, and Zn\textsuperscript{2+} loading was achieved by supplementation with 10 microg/mL Zn\textsuperscript{2+} in the growth medium. High-density cultures (HD) were used for streptozotocin and cytokine toxicities. MIN6 cells were collected, counted, resuspended in DMEM + 15% FBS and plated at HD/low extracellular volume (7.5 x 10\textsuperscript{6} cells/L in 0.04 milliliter) in V-shaped 96 well plates [10]. These HD cultures were plated in 7.5 millimol/L streptozotocin (STZ) or a mixture of cytokines (250 microgram/L IL-1\(\beta\), 8 microgram/L TNF-\(\alpha\), and 200 microgram/L IFN-\(\gamma\)) with coexposure to the compounds tested. High cytokine levels were required due to the HD cultures and short exposure (6 h). Exposure to 15-40 micromol/L Zn\textsuperscript{2+} in serum-free MEM, or to 200-300 micromol/L Zn\textsuperscript{2+} in DMEM + 15% FBS under low density conditions were also utilized. Optimized concentrations of compounds were included during the toxicity exposure as indicated. 2-hydroxy naphthaldenhyde (30-60 micromol/L, Naph), or sirtinol are sirtuin inhibitors; and pyruvate, nicotinamide (10-20 millimol/L), and NAD\textsuperscript{+} (6 millimol/L), restore NAD\textsuperscript{+} levels [13]. Cell viability was assayed at varying times later by 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium Bromide (MTT) staining (0.1% final) of individual wells of a tissue culture plate, and the absorbance at 595 nm was then measured (n = 8-20 wells of cells from at least three independent experiments). Staining with propidium iodide (2.5 milligram/L) for normal density Zn\textsuperscript{2+} toxicity studies followed by measurement of fluorescence was also used. HD cultures were only assayed by MTT because a monolayer culture is required for PI staining [22,23].

Determination of levels of NAD\textsuperscript{+} and NADH

Measurements of NAD\textsuperscript{+} and NADH were made on cell lysates prepared immediately after 4 hr Zn\textsuperscript{2+}, STZ or cytokine exposures. Cells were washed three times to remove compounds followed by lysis in NaOH/EDTA. This lysis was split and part of it directly hydrolyzed at 80°C for 20 min, and the other part acidified followed by hydrolysis at 80°C for 20 min. Alkaline hydrolysis destroys NADH, whereas acid hydrolysis destroys NAD\textsuperscript{+} allowing for their determinations by linked enzymatic cycling reactions. 2 \(\mu\)l of acid extract (\~5000 cells) were added directly to 100 \(\mu\)l of NAD\textsuperscript{+} cycling reagent (100 millimol/L Tris-HCl, pH 8.1, 2 millimol/L \(\beta\)-mercaptoethanol, 2 millimol/L oxaloacetate, 0.3 mol/L ethanol, 0.02% BSA, and yeast alcohol dehydrogenase and 0.5 \(\mu\)g/mL malic dehydrogenase) and incubated at 25°C to obtain 500 cycles of NAD\textsuperscript{+} amplification. Termination by heating at 100°C for 5 min was followed by addition of 1 \(\mu\)l of malate indicator reagent (50 millimol/L amino-methylpropanol (pH 9.9), 5 millimol/L L-glutamate, 0.2 millimol/L NAD\textsuperscript{+}, 5 \(\mu\)g/mL malic dehydrogenase, and 2 \(\mu\)g/mL glutamate oxaloacetate transaminase). This reaction was incubated for 10 min at 25°C. The NADH generated from malate was measured fluorometrically (excitation at 365 nm, emission monitored at 460 nm) [13,24]. For NAD\textsuperscript{+} additions, a correction was made based on NAD\textsuperscript{+} addition and washout from control cultures.

SIRT1 gene expression

Total RNA from harvested MIN6 cells (10\textsuperscript{7}) exposed to 0 or 40 micromol/L Zn\textsuperscript{2+} in serum-free MEM for 3 h was extracted as detailed [25]. The RNA concentration and integrity were verified, and reverse transcription was performed using the iScript CDNA synthesis kit (Bio-Rad, Hercules, CA, USA) on 1 \(\mu\)g of total cellular RNA. Real-time RT-PCR specific primers for SIRT1 and \(\beta\)-actin are as described previously [26]. The reactions were run in duplicate with iQSYBR green Supermix (BioRad) as per manufacturer's instructions. A melt-curve analysis was
performed at the end of each experiment to verify that a single product per primer pair was amplified, and the sizes of the amplified DNA fragments were verified. Samples were compared using the relative CT (the cycle number at the threshold level of log-based fluorescence) method. The percent increase was determined relative to an untreated control culture after normalizing to β-actin expression using $2^{-\Delta\Delta CT}$ (Livak) method.

**Colony maintenance and trials**

The NOD inbred mouse strain (Taconic), the β-cell SIRT1 overexpressing mice (BESTO), and the SIRT1 +/- mice were maintained at LSUHSC’s transgenic animal facility. The SIRT1 +/- and BESTO mice were backcrossed onto a C57/B6j background for maintenance. The BESTO mice, line 431-2, showed a 12-fold overexpression of SIRT1 predominantly in β-cells which resulted in transcriptional regulation of target genes [21]. Housing and anesthesia concurred with the institutional Animal Studies Committee guidelines, the PHS Guide for the Care and Use of Laboratory Animals, USDA Regulations, and the AVMA Panel on Euthanasia. SIRT1 heterozygous knockout animals [27] were backcrossed to NOD mice for 10 generations to syngeneity; SIRT1 +/-/NOD animals develop diabetes and mortality at equivalent ages to the parental NOD animals. Upon interbreeding heterozygous animals, SIRT1 +/- animals die peri-natally whether on an SV129 or an NOD background, but survive on a CD1 background [27,28]. This was a double blind trial (both handler and histologist were blind to genotype) of age-matched female NOD mice with either a SIRT1 +/- or a SIRT1 +/- genotype. Water and food ingestion, and body weight were monitored weekly and did not vary between groups. Fed blood glucose was monitored every Monday afternoon, and fasted blood glucose was determined periodically (glucose oxidase). Fed and fasted blood glucose was measured on days 0, 1, 4, 7, 14, and 21 (n = 20).

**Reagents**

Unless otherwise stated, all reagents were from Sigma Chemical Co (St. Louis, MO).

**Results**

In MIN6 cultures, knockdown of SIRT1 reduced Zn$^{2+}$ toxicities, and overexpression of SIRT1 potentiated Zn$^{2+}$ toxicities

As shown in Figure 2, MIN6 cultures over expressing SIRT1 or an overexpression empty vector control were exposed to A) Zn$^{2+}$ in the absence of serum or B) Zn$^{2+}$ in the presence of serum. SIRT1 overexpression (760% of control) significantly potentiated Zn$^{2+}$ toxicity at all levels of exposure in the presence or absence of serum in β-cells, and sirtuin inhibitors (sirtinol or Naph) attenuated this death. As shown in Figure 3, MIN6 cultures over expressing an siRNA to SIRT1 or an siRNA empty vector control were exposed to A) Zn$^{2+}$ in the absence of serum or B) Zn$^{2+}$ in the presence of serum. SIRT1 knockdown (28% of control) significantly attenuated Zn$^{2+}$ toxicity at all levels of exposure in the presence or absence of serum in β-cells and sirtuin inhibitors did not further reduce this toxicity. Real-time PCR for β-cell SIRT1 expression was performed on control MIN6 cultures 3 h after exposure to 40 micromol/L Zn$^{2+}$, resulting in a 39 ± 4.5% significant increase in expression relative to untreated control at $P < 0.05$ by student t-test (n = 6).

Knockdown of SIRT1 reduced STZ and cytokine toxicities, and overexpression of SIRT1 potentiated them

MIN6 overexpressing SIRT1, or its siRNA, and control cultures were exposed to 7.5 millimol/L STZ (Figure 4), or mixed cytokines (Figure 5) for 6 hours (high density condition-7.5x1010 cells/L, 0.04 milli. in each 96-well V-bottom pit) in the presence or absence of nicotinamide, NAD$^+$, or Naph. These compounds were chosen because they have been previously demonstrated to restore NAD$^+$ levels, and to attenuate Zn$^{2+}$ neurotoxicity. Cell viability was determined by MTT stain-
NAD$^+$ was isolated and measured. Zn$^{2+}$, streptozotocin, and cytokines toxicities, with nicotinamide and NAD$^+$ having the best efficacy. In optimized concentrations as determined by dose responses (data not shown). Micromol/L Zn$^{2+}$, or mixed cytokines for 4 hrs (prior to cell death); induced a significant decrease in NAD$^+$ levels and nicotinamide or NAD$^+$ restored these levels. In addition, SIRT1 knockdown attenuated the loss of NAD$^+$ for Zn$^{2+}$ in the presence or absence of serum. A. Knockdown of SIRT1 (siRNA) and empty vector siRNA control (Control) MIN6 cell lines were assayed as in Figure 1. Cells were grown to 50% confluence exposed as indicated, and cell death determined by propidium iodide staining (5 microg/mL) 20-22 hrs later compared to the complete death induced by 3 millimol/L Zn$^{2+}$ (mean ± SEM, n=12-20 from three independent experiments). B. This cell line was also assayed in the presence of serum (requiring higher Zn$^{2+}$ concentrations) as in A. * signifies difference from Zn$^{2+}$ exposure alone at P < 0.05. $ signifies difference from similarly exposed Control cultures at P < 0.05. Figure 3: SIRT1 knockdown in MIN6 cells attenuated Zn$^{2+}$ toxicity
Stably transfected MIN6 cell lines were established which overexpress a small inhibitory RNA to SIRT1 resulting in knockdown of its expression (28% of control). These cell lines were tested for their sensitivity to Zn$^{2+}$ toxicity in the presence or absence of serum. MIN6 cultures were exposed to 7.5 millimol/L STZ at high density. SIRT1 knockdown, and potentiated by SIRT1 overexpression Figure 4: STZ toxicity in high-density MIN6 cultures was attenuated by SIRT1 knockdown, and potentiated by SIRT1 overexpression MIN6 cultures were exposed to 7.5 millimol/L STZ at high density. SIRT1 denotes the SIRT1 overexpressing line, and siRNA denotes the line which overexpresses the SIRT1 siRNA. Cell survival was assayed by 0.1% MTT staining. # signifies difference from STZ exposure alone; $ signifies difference from similarly exposed control cultures at P < 0.05. mM means millimol/L, STZ means streptozotocin.

Figure 5: Cytokine mediated β-cell death was attenuated by SIRT1 knockdown and was potentiated by SIRT1 overexpression
MIN6 cells were exposed as indicated to cytokines for 6 hrs at high density. Cell survival was assayed by 0.1% MTT staining. In SIRT1 overexpressing MIN6 cells, 2x naphthaldehyde (60 micromol/L) was required for efficacy. β-cell death was attenuated by SIRT1 knockdown, and was potentiated by SIRT1 overexpression of control cultures at P < 0.05. Figure 6: β-cell death was attenuated by SIRT1 knockdown and potentiated by SIRT1 overexpression **• 1000193**
Citation: Sheline CT (2012) Involvement of SIRT1 in Zn\(^{2+}\), Streptozotocin, Non-Obese Diabetic, and Cytokine-Mediated Toxicities of \(\beta\)-cells. J Diabetes Metab 3:193. doi:10.4172/2155-6156.1000193

Figure 6: STZ and Zn\(^{2+}\) reduce NAD\(^{+}\) levels in MIN6 cells which are restored by exogenous NAD\(^{+}\).

MIN6 cells were exposed as indicated for 3 hours. Cells were lysed, NAD\(^{+}\) was extracted and assayed by the enzymatic micro-cycling assay, and the concentration was determined. * signifies a significant difference from control. # indicates a significant difference from 40 micromol/L Zn\(^{2+}\) exposure alone. $ indicates a significant difference from 10 millimolar STZ exposure alone. & indicates a significant difference from cytokine exposure alone at P<0.05.

Table 1: SIRT1 \(\beta\)-cell transgenics trend toward more diabetic incidence after MLDS, and SIRT1 +/- mice trend toward reduced diabetic incidence. Multiple low dose streptozotocin (MLDS) exposure (55 milligram/kg i.p. on 5 consecutive days) was administered to mice (5-10 months of age) as indicated in a blinded fashion. Blood glucose was determined on Day 0, 1, 3, 7, 10, and 14 in a blinded fashion. Diabetic incidence was defined as blood glucose > 2.5 g/L. Mortality was recorded in a blinded fashion on the day that animals displayed akinesia after prodding, or inability to reach food. * indicates difference from BESTO Tg+ mice at P<0.05 by student t-test.

| Animal Condition | Diabetic Animals by 7 days | Diabetic Animals by 14 days | Surviving Animals by 21 days |
|------------------|---------------------------|----------------------------|-----------------------------|
| Multiple Low Dose STZ in BESTO Tg- Ctrl | 9 out of 20 | 12 out of 20 | 11 out of 20 |
| Multiple Low Dose STZ in BESTO Tg+ | 11 out of 20 | 14 out of 20 | 8 out of 20 |
| Multiple Low Dose STZ in SIRT1 +/- | 9 out of 20 | 12 out of 20 | 11 out of 20 |
| Multiple Low Dose STZ in SIRT1 +/- | 6 out of 20 * | 9 out of 20 * | 13 out of 20 * |

Discussion

In these studies we demonstrated that: 1) sirtuin pathway inhibition attenuated Zn\(^{2+}\)-, STZ-, and cytokine-mediated toxicity and NAD\(^{+}\) loss in \(\beta\)-cells, 2) SIRT1 overexpression in MIN6 cell lines potentiated NAD\(^{+}\) loss, and Zn\(^{2+}\), STZ, and cytokine toxicities, 3) SIRT1 knockdown using an siRNA expressing MIN6 cell line attenuated NAD\(^{+}\) loss and these toxicities, 4) diabetic incidence and mortality induced in vivo by streptozotocin or NOD, showed covariance with SIRT1 expression levels upon genetic manipulation.

Zn\(^{2+}\) is toxic to insulinoma cells and to isolated islets, and that zinc chelation and pyruvate can prevent toxicity. Zn\(^{2+}\) chelation and pyruvate attenuate hyperglycemia in the acute high dose streptozotocin model though the NAD\(^{+}\)-dependent mechanism of action was questioned [10,20]. We have utilized several in vitro and in vivo models of T1DM. These include in vitro exposure of \(\beta\)-cells to zinc, mixed cytokines, or STZ, and in vivo exposure to STZ, or the immune-mediated NOD mouse model. STZ and the NOD mouse cause selective death of insulin-secreting \(\beta\)-cells, inducing reductions in nicotinamide cofactor levels, glucose oxidation, and glucose-induced insulin secretion [29-32]. The NAD\(^{+}\) precursor, nicotinamide, reduces diabetic incidence in both the acute high dose, and the multiple low dose streptozotocin injection paradigms [33,34]. Zn\(^{2+}\) preferring chelators (CaEDTA and clioquinol) reduce diabetic incidence in the acute high dose and multiple low dose streptozotocin injection models as demonstrated by the reduction in Zn\(^{2+}\) staining, \(\beta\)-cell death and diabetic symptoms achieved [10,11,20]. We recently demonstrated that pyruvate attenuates multiple low-dose streptozotocin exposure (MLDS) induced-, and NOD-induced diabetes, and that a zinc reduced diet also attenuates NOD-induced diabetes [9].

Our studies in neurons show that an increase in intracellular Zn\(^{2+}\) causes a loss of NAD\(^{+}\) levels that may be partially mediated by sirtuin or poly-ADP ribosyl polymerase (PARP) activation depending on cell type [13,35]. The resultant decrease in the NAD\(^{+}\)/NADH ratio inhibits the energy metabolic pathway at the susceptible enzymes GAPDH and PDH. Pyruvate, nicotinamide, or exogenous NAD\(^{+}\) restore NAD-
levels, and glycolytic flux, and thereby attenuate death. Pyruvate is converted to lactate regenerating NAD⁺ at the expense of NADH [12]. Nicotinamide induces increased synthesis of NAD⁺, or decreases its degradation by NAD⁺-catabolizing enzymes [35]. Nicotinamide is effective in diabetic models [5,36], with therapeutic effects observed only if it is given to prediabetic patients [37–40]. Its mechanism of action is not well defined, with suggestions that it prevents PARP-activation and NAD⁺ depletion, thereby reducing apoptosis of β-cells induced by DNA damage [5]. PARP-induced NAD⁺ depletion is also a mechanism for GAPDH inhibition, resulting in triosephosphate accumulation, and β-cell death in diabetes [41]. However, no reduction in diabetes occurs in the NOD/PARP -/- mouse arguing against a causative role for PARP in this animal model of diabetes [42]. The ability of exogenous NAD⁺ to attenuate Zn²⁺, STZ, and cytokine toxicities in insulinoma cultures argues that NAD⁺ levels are involved in the mechanism. The protective effects of sirtinol and SIRT1 knockdown on NAD⁺ levels and beta-cell death suggested that the sirtuin pathway may be involved.

The sirtuin family (SIRT) and the pancreas

Inhibition of the sirtuin pathway attenuates Zn²⁺ or STZ toxicities of β-cells in part by preventing NAD⁺ depletion [9]; as we have also shown for Zn²⁺-induced neuronal, and β-cell NAD⁺ depletion and toxicities [9,13]. The sirtuin family of proteins are NAD⁺-dependent protein deacetylases resulting in NAD⁺-catabolism, transcriptional silencing, and transcriptional regulation [43]. SIRT1 is ubiquitously expressed; within the pancreas, SIRT1 is expressed strongly in the cytoplasm of β-cells and weakly in both the nucleus and cytoplasm of β-cells [21]. Young β-cell SIRT1 transgenic (BESTO) mice have increased glucose tolerance under basal conditions [21], but lose this effect with age [44]. This suggests that under young physiologic conditions, SIRT1 overexpression may be beneficial, but under pathophysiologic aged T1DM diabetic conditions (MLDS), SIRT1 may be detrimental perhaps due to potentiation of zinc toxicity. Sirtuins appear to mediate part of the NAD⁺ loss after Zn²⁺ and STZ exposures of MIN6 cells, as evidenced by the partial restoration of NAD⁺ levels by sirtuin inhibition for zinc and STZ exposures, but not for cytokine exposures [9]. Sirtuins also act through transcriptional modulation, which may be the predominant mechanism in Zn²⁺-neurotoxicity, and cytokine toxicity in β-cells. SIRT1 overexpression was shown to attenuate IL-1β and IFN-γ induced toxicity in RIN β-cells [45]. However, this study was not done in the presence of TNF-α, or under high-density conditions where zinc release and toxicity could play a role. Recently, SIRT1 was shown to attenuate pancreatic β-cell expansion [46], and to decrease hepatic insulin responsiveness [47]. However, the SIRT1 and AMP kinase activator, resveratrol, suppresses T-cell immune responses, and attenuates diabetic incidence in NOD mice [48]. These effects of resveratrol may be SIRT1 independent, mediated instead by oxidant scavenger or AMP kinase activation mediated mechanisms [49,50]. In age or high-fat diet models of T2DM, SIRT1 activation partially mediates the beneficial effects of NAD⁺ restoration in the peripheral tissues affected by T2DM (liver, WAT, skeletal muscle), though effects on the pancreas or beta-cells were not presented [8]. Similar effects in models of T1DM were not presented.

In these studies, we have implicated the sirtuin pathway and SIRT1 in the pancreatic NAD⁺ loss and beta-cell death induced by the in vitro models of T1DM: Zn²⁺, STZ, or mixed cytokine exposures. We have also suggested that SIRT1 plays a role in the diabetic incidence and mortality induced by the STZ or NOD in vivo models of T1DM. These results differ from those reported for SIRT1 on T2DM induced effects in peripheral tissues, where SIRT1 activity appears to mediate the effects of reducing or increasing NAD⁺ levels [8]. The roles of SIRT1 in pancreatic versus peripheral tissue, and in T1DM versus T2DM appear to be varied and complex, and will require further studies to unravel.

Acknowledgements

Supported by NIH grant DK 073446 (CTS). I would like to thank Shin-Ichi Imai (Washington University) for the BESTO transgenic mice and the MIN6-Sir2OE1, and MIN6-Sir2KD1 cell lines. Dr. Fred Alt (Harvard University) for the SIRT1 knockout mouse line, and Ar-Li Cai and Chunxiao Shi (Washington University) for expert technical assistance with NAD⁺ measurements, and colony maintenance.

Author Contributions

C.T.S. is the guarantor of this manuscript, performed all aspects of this paper, and has no conflicts to report.

References

1. Tisch R, McDevitt H (1996) Insulin-dependent diabetes mellitus. Cell 85: 291-297.
2. Mathis D, Vence L, Benoist C (2001) beta-Cell death during progression to diabetes. Nature 414: 792-798.
3. Obrosova I, Faller A, Burgan J, Ostrow E, Williamson JR (1997) Glycotoxic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galacose-fed rats: effect of an aldose reductase inhibitor. Curr Eye Res 16: 34-43.
4. Trueblood N, Ramasamy R (1998) Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol 275: H75-H83.
5. Kolb H, Burkart V (1999) Nicotinamide in type 1 diabetes. Mechanism of action revisited. Diabetes Care 22: B16-B20.
6. Suarez-Pinzon WL, Mabley JG, Power R, Szabo C, Rabinovitch A (2003) Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmunity in diabetic NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes 52: 1683-1688.
7. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, et al. (2007) Namp/PEPl/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375.
8. Yoshino J, Mills KF, Yoon MJ, Imai S (2011) Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 14: 528-536.
9. Sheline CT, Shi C, Takata T (2012) Dietary Zinc Reduction, Pyruvate Supplementation, or Zinc Transporter 5 Knockout Attenuates Beta-Cell Death in Non-Obese Diabetic Mice, Islets, and Insulinoma Cells. Journal of Nutrition. Accepted.
10. Kim BJ, Kim YH, Kim S, Kim JW, Koh JY, et al. (2000) Zinc as a paracrine effect in pancreatic islet cell death. Diabetes 49: 367-372.
11. Priel T, Aricha-Tamir B, Sekler I (2007) Clioquinol attenuates zinc-dependent beta-cell death and the onset of insulinitis and hyperglycemia associated with experimental type I diabetes in mice. Eur J Pharmacol 565: 232-239.
12. Sheline CT, Behrens MM, Choi DW (2000) Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis. J Neurosci 20: 3139-3146.
13. Cai AL, Zipfel GJ, Sheline CT (2006) Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway. Eur J Neurosci 24: 2169-2176.
14. Sheline CT, Cai AL, Zhu J, Shi C (2010) Serum or target deprivation-induced neuronal death causes oxidative neuronal accumulation of Zn2+ and loss of NAD+. Eur J Neurosci 32: 894-904.
15. Huang XF, Arvan P (1995) Intracellular transport of proinsulin in pancreatic beta-cells. Structural maturation probed by disulfide accessibility. J Biol Chem 270: 20417-20423.
16. Zalweski PD, Millard SH, Forbes IJ, Kapaniris O, Slavotinek A, et al. (1994) Video image analysis of labile zinc in viable pancreatic islet cells using a specific fluorescent probe for zinc. J Histochem Cytochem 42: 877-884.
17. Formby B, Schmid-Formby F, Godsdy GM (1984) Relationship between insulin release and 65zinc efflux from rat pancreatic islets maintained in tissue culture. Diabetes 33: 229-234.
18. Gian WJ, Kennedy RT (2001) Spatial organization of Ca(2+) entry and exocytosis in mouse pancreatic beta-cells. Biochem Biophys Res Commun 286: 315-321.

19. Tartler U, Kroncke KD, Meyer KL, Suschek CV, Kolb-Bachofen V (2000) Nitric oxide interferes with islet cell zinc homeostasis. Nitric Oxide 4: 609-614.

20. Chang I, Cho N, Koh JY, Lee MS (2003) Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes. Diabetologia 46: 1220-1227.

21. Moynihan KA, Grimm AA, Plueger MM, Bernai-Mirzachi E, Ford E, et al. (2005) Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2: 105-117.

22. Sheline CT, Choi DW (1998) Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase. Neurobiol Dis 5: 47-54.

23. Ying H, Gotlin F, Choi D (2000) Assessment of cell viability in primary neuronal cultures. John Wiley & Sons, Inc, New York.

24. Lin SS, Manchester JK, Gordon JI (2001) Enhanced gluconeogenesis and increased energy storage as hallmarks of aging in Saccharomyces cerevisiae. J Biol Chem 276: 36000-36007.

25. Han JH, Strataca C, Rutter WJ (1987) Isolation of full-length putative rat lysophosphatidyl-cDNA using improved methods for mRNA isolation and cDNA cloning. Biochemistry 26: 1617-1625.

26. Becerril S, Rodrigo A, Catalán V, Sáinz N, Ramírez B, et al. (2010) Deletion of Inducible Nitric-Oxide Synthase in Leptin-Deficient Mice Improves Brown Adipose Tissue Function. PLoS One 5: e10962.

27. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, et al. (2003) Functional characteristics of cultured mouse pancreatic islets following exposure to different streptozotocin concentrations. Mol Cell Endocrinol 270: 1036-1042.

28. Mburney MW, Yang X, Jardine K, Hixon M, Boekelheide K, et al. (2003) The mammalian SIRTalpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol 23: 38-54.

29. Strandell E, Eizirik DL, Korosnig O, Sandler S (1988) Functional characteristics of cultured mouse pancreatic islets following exposure to different streptozotocin concentrations. Mol Cell Endocrinol 59: 83-91.

30. Eizirik DL, Sandler S, Welsh N, Hellerstrom C (1988) Preferential reduction of insulin production in mouse pancreatic islets maintained in culture after streptozotocin exposure. Endocrinology 122: 1242-1249.

31. Strandell E, Eizirik DL, Sandler S (1989) Survival and B-cell function of mouse pancreatic islets maintained in culture after concomitant exposure to streptozotocin and nicotinamide. Exp Clin Endocrinol 93: 219-224.

32. Bunik VI (2003) 2-Oxo acid dehydrogenase complexes in redox regulation. Eur J Biochem 270: 1036-1042.

33. Mendola J, Wright JR Jr, Lacy PE (1989) Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozotocin-induced insulitis. Diabetes 38: 379-385.

34. Hassan N, Janjua MZ (2001) The optimum dose of nicotinamide for protection of pancreatic beta-cells against the cytotoxic effect of streptozotocin in albinorat. J Ayub Med Coll Abbottabad 13: 26-30.

35. Sheline CT, Wang H, Cai AL, Dawson VL, Choi DW (2003) Involvement of poly ADP ribose polymerase-1 in acute but not chronic zinc toxicity. Eur J Neurosci 18: 1402-1409.

36. O’Brien BA, Harmon BC, Cameron DP, Allan DJ (2000) Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis. J Pathol 191: 86-92.

37. Visalli N, Costa C, Nato I (1986) [Hypoprolactinemia in subjects with various pathologies of the reproductive system]. Clin Ter 116: 421-423.

38. Pozzilli P, Browne PD, Kolb H (1996) Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care 19: 1357-1363.

39. Behme MT (1995) Nicotinamide and diabetes prevention. Nutr Rev 53: 137-139.

40. Vidal J, Fernandez-Balsells M, Sesmilo G, Aguilara E, Casamitjana R, et al. (2000) Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care 23: 360-364.

41. Wahlberg G, Adamson U, Svensson J (2000) Pyridine nucleotides in glucose metabolism and diabetes: a review. Diabetes Metab Res Rev 16: 33-42.

42. Gonzalez C, Menissier De Murcia J, Janiak P, Bidouard JP, Beauvais C, et al. (2002) Unexpected sensitivity of nonobese diabetic mice with a disrupted poly(ADP-Ribose) polymerase-1 gene to streptozotocin-induced and spontaneous diabetes. Diabetes 51: 1470-1476.

43. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435.

44. Ramsey KM, Mills KF, Satoh A, Imai S (2005) Age-associated loss of Sir2-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sir2-overexpressing (BESTO) mice. Aging Cell 7: 78-88.

45. Lee JH, Song MY, Song EK, Kim EK, Moon WS, et al. (2009) Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway Diabetes 58: 344-351.

46. Bastien-Dionne PO, Valenti L, Kon N, Gu W, Buteau J (2011) Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic beta-cell mass expansion. Diabetes 60: 3217-3222.

47. Erion DM, Yonemitsu S, Nie Y, Nagai Y, Gilum MP, et al. (2009) SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A 106: 11288-11293.

48. Lee SM, Yang H, Tartar DM, Gao B, Luo X, et al. (2011) Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia 54: 1136-1146.

49. Kitada M, Kume S, Inaiuzumi N, Koya D (2011) Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60: 634-643.

50. Um JH, Park SJ, Kang H, Yang S, Foretz M, et al. (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554-563.